Oncoinvent ASA 2024 AR2
The report highlights BerGenBio's sustainability and operational performance for the fiscal year 2024. During the year, the company focused on its lead clinical asset, bemcentinib, particularly in the BGBC016 study for non-small cell lung cancer, which was later discontinued in early 2025. BerGenBio continued to align its operations with the UN Sustainable Development Goals, specifically focusing on health, innovation, and responsible production. The company successfully mapped its greenhouse gas emissions, reporting total emissions of 69.35 t CO2e, with business travel accounting for 97% of the footprint. Additionally, the company maintained a strong focus on diversity, with women representing 62% of its workforce and 50% of its board of directors.
Company: Oncoinvent ASA
Sector: Professional & technical services
Country: Norway
Year: 2024
Type: AR2
Pages: 86
Back to company
Oncoinvent ASA
Annual Report & Accounts
The report highlights BerGenBio's sustainability and operational performance for the fiscal year 2024. During the year, the company focused on its lead clinical asset, bemcentinib, particularly in the BGBC016 study for non-small cell lung cancer, which was later discontinued in early 2025. BerGenBio continued to align its operations with the UN Sustainable Development Goals, specifically focusing on health, innovation, and responsible production. The company successfully mapped its greenhouse gas emissions, reporting total emissions of 69.35 t CO2e, with business travel accounting for 97% of the footprint. Additionally, the company maintained a strong focus on diversity, with women representing 62% of its workforce and 50% of its board of directors.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Women on Board
Women in Management
Workplace Fatalities
Employees